These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8846242)

  • 41. Should the hematocrit (hemoglobin) be normalized in Pre-ESRD or dialysis patients? Yes!
    Besarab A; Aslam M
    Blood Purif; 2001; 19(2):168-74. PubMed ID: 11150804
    [No Abstract]   [Full Text] [Related]  

  • 42. Should the hematocrit be normalized in dialysis and in pre-ESRD patients?
    Macdougall IC
    Blood Purif; 2001; 19(2):157-67. PubMed ID: 11150803
    [No Abstract]   [Full Text] [Related]  

  • 43. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.
    Thamer M; Zhang Y; Kaufman J; Kshirsagar O; Cotter D; Hernán MA
    Am J Nephrol; 2014; 40(6):554-60. PubMed ID: 25592645
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
    Wilhelm-Leen ER; Winkelmayer WC
    Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Case management of the anemic patient: epoetin alfa--focus on adequacy of dialysis.
    Erlich L
    ANNA J; 1993 Apr; 20(2):181-4. PubMed ID: 8512376
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.
    Besarab A; Bolton WK; Browne JK; Egrie JC; Nissenson AR; Okamoto DM; Schwab SJ; Goodkin DA
    N Engl J Med; 1998 Aug; 339(9):584-90. PubMed ID: 9718377
    [TBL] [Abstract][Full Text] [Related]  

  • 47. How to design an anemia management protocol.
    Senger JM; Trenkle JA; St John WD
    ANNA J; 1998 Apr; 25(2):235-40. PubMed ID: 9801503
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
    Mohini R
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reduced responsiveness to epoetin at re-exposure after prolonged epoetin-free period in anemic hemodialysis patients with end-stage renal disease.
    Milutinović S; Trkulja V
    Croat Med J; 2006 Jun; 47(3):424-32. PubMed ID: 16758521
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical administration of epoetin alfa recombinant.
    Taylor BA; Weinstein SM
    J Intraven Nurs; 1992; 15(2):78-82. PubMed ID: 1564606
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epoetin alfa--focus on dialyzability. Case study of the anemic patient.
    Keen ML
    ANNA J; 1995 Dec; 22(6):610-3. PubMed ID: 8633909
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Erythropoietin and iron use in peritoneal dialysis patients. Report from the 1997 HCFA end-stage renal disease core indicators project.
    Bailie GR; Frankenfield DL; Prowant BF; McClellan W; Rocco MV
    Am J Kidney Dis; 1999 Jun; 33(6):1187-9. PubMed ID: 10352214
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease.
    Grabe DW
    Am J Health Syst Pharm; 2007 Jul; 64(13 Suppl 8):S8-14; quiz S23-5. PubMed ID: 17591995
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
    Jalil R; Vaccarezza A; Jara A; Lira P; Vial S; Serrano V
    Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Monitoring considerations in recombinant human erythropoietin therapy.
    Ogden DA
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):12-5. PubMed ID: 2669080
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anemia management in pediatric dialysis patients. Case study of the anemic patient.
    Currier H
    ANNA J; 1999 Jun; 26(3):349-52. PubMed ID: 10633609
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Case study of the anemic patient: epoetin alfa--focus on blood pressure.
    Chambers JK
    ANNA J; 1994 Apr; 21(2):154-7. PubMed ID: 8080316
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epoetin alfa--focus on the rehabilitation of dialysis patients. Case study of the anemic patient.
    Martin-Lester M
    ANNA J; 1996 Dec; 23(6):630-3. PubMed ID: 9069794
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Case management of the anemic patient. Epoetin alfa: focus on kinetic dosing.
    Keen ML
    ANNA J; 1990 Aug; 17(4):318-9. PubMed ID: 2396859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.